Latest Development of International Pharmacovigilance and Its Implications

doi:10.19803/j.1672-8629.2020.12.04

Abstract

Abstract: As a predictor of development of global pharmacovigilance, the Annual Meeting of WHO Program of International Drug Monitoring (PIDM) is an important event for us to find out hotspots and latest progress in pharmacovigilance worldwide. Based on the agenda of the 42nd Annual Conference held in 2019, this paper analyzes the latest developments of global pharmacovigilance and implications for China. It is believed that the scope of pharmacovigilance has been expanded from adverse reaction monitoring to the detection, reporting and prevention of drug abuse, misuse and medication errors, and that the focus is gradually shifting from drug safety to patient safety. Therefore, there is an urgent need to continue to enhance the awareness of social drug vigilance and streamline public participation. In addition, the application of new generation information technology represented by artificial intelligence (AI) in the field of pharmacovigilance is making a breakthrough, and it has become an international consensus to actively promote smart supervision and smart safety surveillance.

Key words: pharmacovigilance awareness, medication error, smart safety surveillance, artificial intelligence

CLC Number:

R969.3

CHEN Feng. Latest Development of International Pharmacovigilance and Its Implications[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 867-870.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.2020.12.04

https://www.zgywjj.com/EN/Y2020/V17/I12/867

References

[1] Liu P.Implement "the Four Strictest Principles" and Strictly Observe Drug Safety-Publicity and Implementation of the Newly Revised Drug Administration Law of the People' s Republic of China[J].China Pharmaceuticals(中国药业),2019,28(24):1-3.
[2] Song HL.The construction of the vaccine management system and the innovation of the legal system-legislative interpretation of the "People's Republic of China Vaccine Management Law"[J].China Food Drug Administration(中国食品药品监管),2019(7):4-12.
[3] NMPA.National adverse drug reaction monitoring and evaluation work video conference held[EB/OL].(2020-05-19)[2020-06-06].http://www.nmpa.gov.cn/WS04/CL2056/377524.html.
[4] Cao LY,Wu GZ,Tian CH.Strengthen international comm-unication &cooperation to promote global drug monitoring[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2006,3(3):150-152.
[5] World Health Organization (WHO).42nd Annual Meeting of Representatives of National Pharmaco vigilance Centres Participating in the WHO Progr amme for International Drug Monitoring[J].WHO Pharmaceuticals Newsletter,2019(6):25.
[6] World Health Organization (WHO).WHO Global Benchmarking Tool (GBT) for evaluation of national regulatory systems [EB/OL].[2020-06-06].https://www.who.int/medicines/regulation/benchm-arking_tool/en/.
[7] Caster O,Aoki Y,Gattepaille LM,et al.Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets:Recom mendations for Limiting False-Positive Associations[J].Drug Safety,2020(43):479-487.
[8] Uppsala Monitoring Center.What is VigiBase?[EB/OL][2020-06-06].https://www.who-umc.org/vigibase/vigibase/.
[9] U.S.Food and Drug Administration (FDA).MedWatch:The FDA Safety Information and Adverse Event Reporting Program [EB/OL].[2020-06-06].https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.
[10] U.S.Food and Drug Administration (FDA).FDA Adverse Event Reporting System[EB/OL].[2020-06-06].https://www.fda.gov/drugsdrug-approvals-and-databases/fda-adverse-event-reporting-system-faers.
[11] Thomas L,Carol P,Oanh D,et al.Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology[J].Journal of Biomedical Informatics,2018,83(7):73-86.
[12] Jiang J,Hou YF,Liu XJ,et al.Overview of adverse drug reaction signal detection methods[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2010,7(2):78-80.
[13] World Health Organization (WHO).Meeting postponed.[EB/OL].[2020-06-06].https://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/ICDRA2020/en/.http://www.nmpa.gov.cn/WS04/CL2199/337981.html.
[14] NMPA.Notice of the State Drug Administration on printing and distributing the action plan of the State Drug Administration on accelerating the promotion of smart drug supervision[EB/OL].(2020-05-24)[2020-06-06].http://www.nmpa.gov.cn/WS04/CL2199/337981.html.
[15] NMPA.The State Food and Drug Administration launches China's drug regulatory scientific action plan[EB/OL].(2020-04-30)[2020-06-06].http://www.nmpa.gov.cn/WS04/CL2056/337150.html.